(Press-News.org) Today, individuals with lupus nephritis benefit from better treatments than a decade ago, according to a review appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The article suggests that patients with the disease can now live full lives without suffering from many treatment-related side effects that plagued them in the past. In the future, patients will likely experience additional benefits from treatment strategies currently being explored in clinical trials.
Individuals with the autoimmune disease systemic lupus erythematosus (SLE) can experience a number of medical complications, such as lupus nephritis, an inflammatory kidney disorder. Lupus affects about 1.4 million persons in the US (particularly women aged 20 to 40 years of age); it can be serious and lead to kidney failure. Researchers have been vigorously studying therapies for the condition in recent years and made significant advances that have helped affected individuals.
Gerald Appel, MD and Andrew Bomback, MD (Columbia University College of Physicians and Surgeons) recently reviewed the various breakthroughs in lupus nephritis research over the past 10 years. They note that improved classification of different classes of the condition now guide therapy. New treatment regimens use lower doses and shorter treatment durations of intravenous cyclophosphamide, a highly toxic immunosuppressive drug—a change that has reduced treatment-related side effects without sacrificing efficacy. In addition, the less toxic immunosuppressive agent mycophenolate mofetil has emerged as a viable alternative to cyclophosphamide for certain classes of lupus nephritis. Also, combination treatments with multiple agents have provided greater benefits than single drugs for many patients.
New therapies that target specific components of the immune system are also proving useful. For example, rituximab, an antibody that depletes B cells, may induce remissions in some patients with severe lupus nephritis, including those whose condition does not respond to cyclophosphamide or mycophenolate mofetil. Other targeted agents include ocrelizumab and belimumab, which also act on B cells, as well as abatacept, which blocks T cell activation. Finally, recent clinical trials have shown that once a patient is in remission, mycophenolate mofetil and azathioprine are effective for preventing relapses.
"Treatment of lupus nephritis is rapidly changing, becoming safer and more effective," said Dr. Appel. Because the disease still negatively affects many individuals, though, investigators continue to seek out new therapies and new regimens based on old therapies. "The treatment of lupus nephritis today is markedly different, and objectively more effective, than it was 10 years ago. The hope and expectation is that a similar claim will be made 10 years hence," the authors wrote.
###
Disclosures: Dr. Bomback and Dr. Appel received research support from Genentech, Roche, Aspreva-Vifor, Novartis, Teva, Alexion, and Questcor. Dr. Bomback has served as a consultant for Novartis and Questcor. Dr. Appel has served as a consultant for Genentech, Roche, Bristol-Myers Squibb, Teva, and Questcor.
The article, entitled "Brief Review: Updates on the Treatment of Lupus Nephritis," will appear online at http://jasn.asnjournals.org/ on November 1, 2010, doi 10.1681/ASN.2010050472.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, the American Society of Nephrology (ASN) is the world's largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians.
END
Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density, according to a study published online in The Journal of the National Cancer Institute.
Lasofoxifene is a SERM, or selective estrogen receptor modulator, that, like tamoxifen, blocks the effects of estrogen in breast tissue. Another SERM, raloxifene, has been shown to reduce breast cancer risk. In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, a double-blind, placebo-controlled, ...
CAMBRIDGE, Mass. -- Researchers at Harvard University say America's obesity epidemic won't plateau until at least 42 percent of adults are obese, an estimate derived by applying mathematical modeling to 40 years of Framingham Heart Study data.
Their work, published this week in the journal PLoS Computational Biology, runs counter to recent assertions by some experts that the obesity rate, which has been at 34 percent for the past five years, may have peaked. An additional 34 percent of American adults are overweight but not obese, according to the federal government's ...
Chevy Chase, MD—The beneficial effects of six months of testosterone treatment on muscle mass, strength and quality of life in frail elderly men are not maintained at six months post-treatment, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
Frailty is an age-related state of physical limitation caused by the loss of muscle mass and function and can lead to adverse clinical outcomes such as dependency, institutionalization and death. Testosterone levels naturally decline with aging and testosterone ...
Chevy Chase, MD—Researchers may have identified a promising novel diagnostic biomarker for ectopic pregnancy, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). In the western world, deaths from ectopic pregnancy are not common but in the developing world one in ten women who are admitted with an ectopic pregnancy die.
An ectopic pregnancy is an abnormal pregnancy that occurs outside the uterine cavity. Most ectopic pregnancies take place in the Fallopian tube but implantation can also occur ...
LA JOLLA, CA – November 2, 2010 – Embargoed by the journal Cell Stem Cell until November 4, noon, Eastern time – Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.
Researchers already know that the disease arises from the silencing of the gene FXN, due to an abnormally expanded stretch of DNA within the gene. The length of this "triplet repeat expansion" determines the degree of gene silencing, ...
Researchers have identified the deletion of a genomic region on chromosome 17 as a significant risk factor for autism spectrum disorders (ASD) and schizophrenia. A mutation of one of the genes in the deleted interval already is a known cause of renal cysts and diabetes syndrome (RCAD).
The research, by an international collaboration of scientists led by Emory University, will be published in the American Journal of Human Genetics. Lead author of the study is Daniel Moreno-De-Luca, MD, MSc, Emory postdoctoral fellow in the Department of Human Genetics. Senior authors ...
LA JOLLA, CA—A study by researchers at the Salk Institute for Biological Studies revealed that stem cells can sense a decrease in available nutrients and respond by retaining only a small pool of active stem cells for tissue maintenance. When, or if, favorable conditions return, stem cell numbers multiply to accommodate increased demands on the tissue.
Elucidating the mechanisms by which hormonal signaling influences stem cell behavior under normal conditions and in response to stress provides important insights into the activities of stem cells in regenerative medicine, ...
Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed.
New research, published today in the journal Science, reveals that a type of stromal cell found in many cancers which expresses fibroblast activation protein alpha (FAP), plays a major role in suppressing the immune response in cancerous tumours – thereby restricting the use of vaccines and other therapies which rely on the body's immune system to work. They ...
Scientists at the Wellcome Trust Centre for Human Genetics, University of Oxford, have identified a genetic variant which influences whether a person with dyslexia is more skilled with either the left or right hand. The finding identifies a novel gene for handedness and provides the first genetic evidence to support a much speculated link between handedness and a language-related disorder.
The majority of people worldwide are right-handed. Since the left side of the brain controls the right side of the body, and vice versa, this implies that for most people the left hemisphere ...
WASHINGTON, DC: A new report from the Project on Emerging Nanotechnologies (PEN) at the Woodrow Wilson International Center for Scholars explores a variety of voluntary options available for the oversight of nanotechnology products and processes. The report, Voluntary Initiatives, Regulation, and Nanotechnology Oversight: Charting a Path, by Dr. Daniel Fiorino, Director of the Center for Environmental Policy at American University, provides a historical overview of voluntary approaches to environmental protection and assesses their applicability to the emerging field of ...
